Bioventus (NYSE:BVS) Trading Down 1.1% – Time to Sell?

Bioventus Inc. (NYSE:BVS)’s stock price traded down 1.1% on Tuesday . The stock traded as low as $7.34 and last traded at $7.45. 291,511 shares were traded during trading, a decline of 21% from the average session volume of 369,373 shares. The stock had previously closed at $7.53.

Bioventus Trading Down 1.1%

The stock’s fifty day simple moving average is $7.32 and its 200-day simple moving average is $7.03. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a market cap of $616.58 million, a PE ratio of -12.21 and a beta of 0.79.

Insiders Place Their Bets

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $7.42, for a total value of $131,341.42. Following the completion of the transaction, the director directly owned 56,997 shares in the company, valued at $422,917.74. This trade represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Guy P. Nohra sold 10,000 shares of Bioventus stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $7.57, for a total value of $75,700.00. Following the sale, the director directly owned 116,610 shares of the company’s stock, valued at $882,737.70. This trade represents a 7.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 33.00% of the company’s stock.

Institutional Trading of Bioventus

Hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after acquiring an additional 1,538 shares in the last quarter. Covestor Ltd grew its stake in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares during the period. Harbor Capital Advisors Inc. increased its holdings in shares of Bioventus by 12.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 24,482 shares of the company’s stock valued at $162,000 after purchasing an additional 2,615 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Bioventus by 24.1% in the 1st quarter. EP Wealth Advisors LLC now owns 17,490 shares of the company’s stock valued at $160,000 after purchasing an additional 3,394 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Bioventus by 28.3% during the second quarter. The Manufacturers Life Insurance Company now owns 17,855 shares of the company’s stock worth $118,000 after buying an additional 3,935 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.